Global Conjunctivitis Market 2015-2019 Examines Increased Exposure to Chemicals and Pollutants / Patent Expiry of Medication / Strategic Alliances and M&A

19 Feb, 2016, 08:10 ET from Research and Markets

DUBLIN, Feb. 19, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/6dsq4s/global) has announced the addition of the "Global Conjunctivitis Market 2015-2019" report to their offering.

The analysts forecast the global conjunctivitis medication market to grow at a CAGR of 1.94% during the period 2015-2019.

Conjunctivitis, also called pink eye or Madras eye, is an infection in or inflammation of the conjunctiva. It affects either one or both a person's eyes and can be the result of an allergy, bacteria, or a virus. Allergens such as smoke, pollen, dust mites, eye drops, cosmetics, and perfumes can lead to conjunctivitis. It is usually associated with redness of the eye along with the release of mucoid discharges. Although the condition usually heals without medication, antibiotics are commonly used for treatment to avoid complications due to irritation of the eye.

The report covers the present scenario and the growth prospects of the global conjunctivitis medication market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of various prescription medication along with the over-the-counter (OTC) medication used to treat bacterial, viral, and allergic conjunctivitis. The report also includes a discussion of the key vendors operating in this market.

M&A between companies is expected to increase the market penetration of conjunctivitis medication, stimulating the growth of the market. Combination therapy is also an efficacious treatment option for individuals affected by conjunctivitis.

According to the report, increased exposure to harmful pollutants and chemicals is leading to a rise in the number of conjunctivitis cases worldwide. People working in chemical factories and those exposed to automobile exhaust tend to acquire allergic conjunctivitis. The rising awareness of the condition and its treatment options are driving market growth.

Further, the report states that as patents of existing therapies expire, genericization of treatment medication is expected to occur. This will lead to the entry of low-cost generics into the market, reducing overall revenue. In addition, the reluctance of physicians toward the acceptance of new therapies is a challenge to market growth.

Key vendors

- Akorn

- Alcon

- Allergan

- Bausch & Lomb

Other prominent vendors

- Celsus Therapeutics

- Eleven Biotherapeutics

- Griffin Discoveries

- InSite Vision

- Merck

- Nicox

- NovaBay

- Ocular Therapeutix

- Santen Pharmaceutical

- Shire (Foresight Biotherapeutics)

- Starpharma

- Sun Pharmaceutical

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Overview: Conjunctivitis

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation based on condition type

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/6dsq4s/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com